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RANSMISSION through sexual contact ac-
counts for 75 to 85 percent of the nearly 28
million infections with the human immuno-
deficiency virus (HIV) that have occurred so far.1
The probability of infection through sexual contact,
although it varies greatly, appears to be lower than
that of infection through other routes of exposure
(Fig. 1). The variability observed among and within
routes of HIV exposure depends partly on the viral
dose and also on whether the virus is transmitted di-
rectly into the blood or onto a mucous membrane.
In addition, these differences are influenced by a va-
riety of host factors, including both factors common
to all routes of exposure and those unique to sexual
transmission.
HIV infectivity is the average probability of trans-
mission to another person after that person is ex-
posed to an infected host. Infectivity plus two other
parameters — the duration of infectiousness and the
average rate at which susceptible people change sex-
ual partners — determines whether the epidemic
grows or slows.12 On a population level, all three
corners of the classic epidemiologic triangle — host-
related factors (susceptibility and infectiousness), en-
vironmental factors (the social, cultural, and political
milieu), and agent factors (HIV type 1) determine
HIV infectivity. Host-related and environmental fac-
tors can amplify the epidemic through their dual ef-
fect on infectivity and the rate of sexual-partner
change. Although the entire triangle is key to under-
standing infectivity, our article focuses on the epide-
miology and biology of the host-related factors that
affect the sexual transmission of HIV.
HOST SUSCEPTIBILITY AND 
INFECTIOUSNESS
Host susceptibility depends on viral entry into
cells through CD4 and chemokine surface recep-
tors.13,14 These cells include CD4 T lymphocytes,
T
Langerhans’ cells, and other macrophages. In macaques,
virus appears in dendritic cells of the vaginal lamina
propria soon after vaginal inoculation with simian
immunodeficiency virus (SIV).15 HIV-receptive cells
have been found in the lamina propria of oral, cer-
vicovaginal, foreskin, urethral, and rectal epithelia in
other primate models.16
In women, the glandular epithelium harbors HIV
in the zone of transformation between the columnar
and squamous cells of the cervix.17 Cervical swabs
yield HIV DNA more readily than vaginal swabs
(33 percent vs. 17 percent).18 In men, HIV is detect-
able in seminal cells and seminal plasma. Although
sperm cells do not express CD4 receptors and are
unlikely to be a major source of infection, HIV DNA
has been detected in some sperm cells and their pre-
cursors.19
Host factors affecting infectivity have been identi-
fied through both population-level studies of HIV
transmission and direct measurement of virus in gen-
ital secretions (Table 1). These factors may operate
through several interrelated mechanisms. Host sus-
ceptibility may be affected by factors linked to in-
flammation or immune activation that alter either the
number of susceptible target cells or the receptivity of
those cells. In addition, these same mechanisms may
affect the production of virus within infected cells,
thereby influencing the infectiousness of the host.
For example, during immune activation after vaccina-
tion with tetanus toxoid, the blood concentration of
virus increases 2- to 36-fold.20 Other factors may in-
duce microscopic erosions that provide the virus direct
access to the bloodstream. Still others may act by fa-
cilitating the survival of HIV in the oral, genital, or
rectal mucosa. The vaginal pH may affect the survival
of HIV under some conditions.21
Host Genetics
Epidemiologic data suggest that occasionally hosts
may lack susceptibility to HIV infection.14,22 Some
sex workers and homosexual men remain uninfected
despite repeatedly having unprotected sexual inter-
course with HIV-infected partners.14,22-24 A mutation
in the chemokine-receptor gene has been identified.24
This mutation apparently varies greatly according to
race, with 11 percent and 1.7 percent homozygosity
among whites and blacks, respectively. People who
are homozygous for the CKR5 mutation appear to
be resistant to infection. While heterozygosity for this
mutation does not prevent infection, it may slow the
progression of the disease. The effect of heterozygos-
ity on HIV infectiousness is unknown.
Stage of Infection
A late stage of infection is a strong predictor of in-
fectiousness according to both epidemiologic and bi-
ologic data. When the index partner has more ad-
vanced HIV infection — indicated by symptoms of
HIV disease, a diagnosis of the acquired immunode-
ficiency syndrome (AIDS), CD4 counts below 200
cells per cubic millimeter, or p24 antigenemia —
sexual partners are at a much higher risk of acquiring
infection (relative-risk range, 6.1 to 17.6).25-30
Host infectiousness is likely to increase as a func-
tion of the concentration of virus in the genital
tract. Higher viral loads in the blood have been as-
sociated with the transmission of HIV to sexual part-
ners of people with transfusion-acquired infections.31
Data on viral concentration in blood and semen
generally support the epidemiologic inferences about
the importance of the stage of infection in the trans-
mission of HIV. Recent studies show that HIV is
more readily detected, and in some cases is present in
higher concentrations, in the blood32,33 or semen34,35
of men with low CD4 T-lymphocyte counts or more
advanced HIV disease than in that of men with high-
er counts or less advanced disease. This correlation
was not observed in some studies,19,36-40 however,
and two small studies of the stage of infection and
concentrations of HIV in cervicovaginal fluids also
found no relation.41,42
Primary infection (which occurs during the peri-
od between exposure to HIV and the appearance of
HIV antibodies) may also be associated with increased
infectiousness.5,12,43,44 Across studies, blood viral ti-
ters in men at about the time of seroconversion45-47
are higher than in men in later stages of infec-
tion.32,33,45 Although the concentration of HIV in
genital secretions during primary infection has not
been determined, epidemiologic evidence supports a
peak in the transmissibility of HIV soon after a per-
son is infected. The probability of infection was
greater when high-risk sexual behavior occurred ear-
ly in the epidemic, presumably because of the large
proportion of people with primary infection at that
time.48 The fact that the probability of female-to-
male transmission per contact is higher in Thailand3
(0.056) than in Europe2 and the United States49
(0.0003 to 0.0014) may reflect the more recent
introduction of HIV to Asia. The Thai estimate is in
the range reported for male-to-male infectivity in
the early years of the U.S. epidemic.6,43,50 Primary
infection may account for a great part of the risk of
transmission, according to modeling estimates.5,43,44
The large contribution to the propagation of the ep-
idemic may be attributed to the association of pri-
mary infection with two parameters that influence
the spread of HIV — higher infectivity and a high-














































Figure 1. Per-Contact Probability of HIV Transmission.
The infectivity ranges for sexual contact are derived from a comprehensive review of the literature
(lower and upper bounds are from modeling per-contact transmission in different study populations
with different modeling techniques). Each infectivity estimate for the other routes of infection origi-
nates from one representative study. The routes of infection are as follows: sexual intercourse, with
 indicating female-to-male transmission,2,3 indicating male-to-female transmission,2,4 and
indicating  male-to-male transmission5,6; needle stick7; needle sharing8; transmission from moth-
er to infant with9 and without10 perinatal zidovudine treatment; and transfusion.11
Antiretroviral Therapy 
Antiretroviral therapy may affect infectivity. De-
creases in concentrations of and detection of seminal 
HIV in men taking zidovudine or newer antiretrovi-
ral drugs have been observed in some33,51 but not 
all36,37,40,52 studies. Antiretroviral therapy apparently 
does not affect the detection of HIV in cervicovagi-
nal specimens.41,42 However, such therapy is associat-
ed with a 50 percent reduction in the sexual trans-
mission of HIV.53 The effect on susceptibility to 
infection of administering antiretroviral agents imme-
diately after sexual exposure to HIV is unknown,54 al-
though administering zidovudine decreases the risk 
of infection after needle-stick injuries.55 Arguments 
for antiretroviral prophylaxis after sexual exposure to 
HIV must be carefully weighed against the cost and 
toxicity of the drugs, as Katz and Gerberding point 
out elsewhere in this issue of the Journal.54 Finally, 
antiretroviral drugs slow the progression of the dis-
ease and thus have an effect on the stage of infection.
Reproductive Tract Infections
The presence of reproductive tract infections is 
strongly associated with susceptibility to HIV, even
after adjustment for sexual behavior.56 The preva-
lence of genital ulcer disease (chancroid, syphilis, or
herpes) is associated with an increased relative risk of
HIV infection, ranging from 1.5 to 7.0 in both men3,57
and women.25,26,58,59 Gonorrhea and chlamydia and
trichomonas infection are associated with a relative
increase of 60 to 340 percent in the prevalence of
HIV infection in men3,25,59 and women.26,59-61 Bacte-
rial vaginosis has also been shown to be associated
with HIV infection.61 In women, genital ulcer dis-
ease may have a potentiating effect on the incidence
of HIV infection.62
Measurement of HIV in genital secretions indicates
that HIV infectiousness may be greater in the pres-
ence of concurrent reproductive tract infections. For
men the data are consistent. Seminal leukocytosis,35
urethritis,63-65 gonorrhea,63,64 and cytomegalovirus in-
fection37 are associated with increased detection of
HIV in semen. Treatment of urethritis diminishes the
detection of HIV in the urethra63 and the concentra-
tion of HIV in semen.64 For women the data are
scarce and inconsistent. A twofold increase in HIV
detection associated with sexually transmitted diseases
or with purulent cervical secretions has been ob-
*The associations represented were statistically significant in at least one study. The degrees of pos-
itivity (↑ to ↑↑↑) and negativity (↓ to ↓↓↓) of the associations are indicated with arrows, with three
arrows indicating a very strong association. The symbol ↓↑ denotes that there is evidence in support
of both a positive and a negative association. A question mark indicates an unknown or hypothesized
association that is not currently supported by data.
TABLE 1. BIOLOGIC HOST-RELATED FACTORS AFFECTING SEXUAL 
TRANSMISSION OF HIV.*









Mutation of chemokine-receptor gene ? ? ↓↓↓
Late stage of HIV infection ↑↑ ↑↑↑ Not 
applicable
Primary HIV infection ↑↑ ↑↑ Not 
applicable
Antiretroviral therapy ↓ ↓↓ ↓?
Local infection (inflammation or ulcer of re-
productive tract or rectal or oral mucosa)
↑↑ ↑ ↑↑
Presence of cervical ectopy ↑↑ ↑? ↑↑


















Menstruation ? ↑↑ ↑
Factors that lower cervicovaginal pH ↓? ↓? ↓?
Immune activation ↑? ↑ ↑
Genital tract trauma ↑? ↑↑ ↑↑
Pregnancy ↑↑ ↑? ↑?
served in two studies of women,18,42 but no associa-
tion was noted in another.66 In the negative study,
however, cervical inflammation correlated with HIV
detection. One study of HIV transmission demon-
strated that men were more likely to seroconvert after
sexual contact with women who had concurrent gen-
ital ulcer disease.67 These findings suggest that genital
ulcers cause an increase in infectiousness.
Cervical Ectopy
Cervical ectopy (replacement around the cervical
os of normal multilayered cervical squamous cells
with glandular, single-layered columnar cells that are
typically found inside the os) often leaves cervical
tissues more friable. Cervical ectopy has been iden-
tified as a risk factor for the acquisition of HIV infec-
tion (relative risks ranging from 1.7 to 5.0) in some62,68
but not all69 of the studies of this association. HIV is
five times as likely to be detected in women with ecto-
py as in those without.18
Male Circumcision
Male circumcision consistently shows a protective
effect against HIV infection.70 This may be due to
the abundance of Langerhans’ cells in the foreskin
or to a receptive environment for HIV in the sulcus
between the foreskin and glans. The prevalence of
HIV infection is 1.7 to 8.2 times as high in men
with foreskins as in circumcised men, and the inci-
dence of infection is 8 times as high. A greater pro-
portion of the sex partners of uncircumcised men
than of circumcised men are infected with HIV, which
suggests that the presence of the foreskin may also
increase infectiousness.28,71
Contraception
The choice of contraceptive method affects the like-
lihood of HIV transmission.72,73 Condoms, used con-
sistently, protect both sexes against HIV.25,27,29,53,74
Spermicides containing nonoxynol 9 protect against
bacterial infections of the reproductive tract, but
their effect against HIV is uncertain.72,73 Further-
more, these compounds may cause vaginal irrita-
tion.72,73 One study found that the use of intrauter-
ine devices carried an increased risk of HIV infection
(odds ratio, 3.0),26 but another did not.69 Conflict-
ing results have also been reported for hormonal
contraceptives. Some investigators report an increased
relative risk (range, 2.0 to 4.5),72,75-77 possibly due to
increased cervical ectopy69-78 or thinning of the vag-
inal epithelia.79 Others report a protective effect (rel-
ative risk, 0.6)26,68 or no effect.62-69 In HIV-seropositive
women, cervical HIV shedding strongly correlated
with the use of oral contraceptives in one study18 but
not in another.66
Menstruation and Pregnancy
Sex during menstruation may increase women’s
risk of acquiring HIV infection (odds ratio, 1.5),26
as may bleeding during sexual intercourse (odds
ratio, 4.9).28 Men who have sex with HIV-infect-
ed women during menstruation are 3.4 times as
likely to have HIV infection as those who do not,27
even though intermittent secretion of HIV occurs
throughout the menstrual cycle.66,80 During preg-
nancy, infected women are two to three times
as likely to have HIV detected in genital secre-
tions.18,42,66
ENVIRONMENT
The HIV epidemic, like any other, occurs within a
complex social environment.81 Social norms that af-
fect infectivity include specific sexual practices (e.g.,
anal-receptive intercourse),82 patterns of sexual part-
nering, contraceptive choices, and the use of sub-
stances that lower sexual inhibitions. Environmental
factors also affect the average rate of sex-partner
change, which may affect the growth of the epidem-
ic dramatically. Such factors include the presence
of unregulated commercial-sex facilities, “crack” co-
caine houses, and bathhouses, as well as social norms
that affect the average number and concurrency of
sex partnerships.44,83,84 Geographic differences in the
length of time the epidemic has been present in a
community lead to differences in both the local prev-
alence of HIV infection and the number of people
with AIDS. The former affects the probability of ex-
posure to infection; the latter has an effect on aware-
ness of the epidemic, which in turn influences both
individuals’ behavior and the social response. Expo-
sure to risky environmental factors indicates a social
vulnerability that largely parallels the maldistribu-
tion of social and economic resources — a macro-
scopic force shaping the epidemic.85
BIOLOGIC AGENT
The properties of HIV itself may also influence
transmission. HIV subtypes have distinct geographic
distributions, with A, C, D, and E predominant in
sub-Saharan Africa and Asia and B predominant in
the United States, the Caribbean, South America,
and Western Europe.86 Subtype E, the most com-
mon subtype in Thailand, is reported to have a great-
er tropism for Langerhans’ cells than subtype B.87
This tropism may contribute to the rapid epidemic
spread of HIV through Thailand and the high per-
contact transmission rate observed there.3 High con-
centrations of HIV in semen specimens from sub-
Saharan Africa may reflect differences among HIV
clades in the ability to replicate in vivo.65
There appear to be phenotypic differences be-
tween isolates in blood and those in semen. Non–
syncytia-inducing viral isolates that are macrophage-
tropic are found early in HIV disease and may
be better adapted to spreading than lymphocyto-
tropic organisms.88 Particular viral-envelope genetic
sequences are required for vaginal transmission of
chimeric simian–human immunodeficiency viruses.89 
Genotypic differences in the viral envelope in blood 
as compared with genital specimens have been re-
ported in women.90 In addition, other phenotypic 
differences between HIV harvested from blood plas-
ma and that harvested from genital secretions may 
affect the efficiency of transmission.88 Antiretroviral-
drug resistance, for example, appears in cell-free and 
cell-associated virus in the blood and semen at dif-
ferent times.91
THE FUTURE: PREVENTING SEXUALLY 
TRANSMITTED HIV INFECTION
Strategies for preventing the sexual transmission 
of HIV have focused on three main areas: encourag-
ing the use of condoms, treating sexually transmit-
ted diseases, and reducing the amount of unsafe sex-
ual behavior (by promoting sexual abstinence or 
decreased numbers of partners).92 The combination 
of these strategies involves intervention at all three 
corners of the epidemiologic triangle for the infec-
tivity parameter as well as for the contact-rate pa-
rameter of the epidemic. Several population-level 
interventions have helped reduce the sexual spread 
of HIV. For example, Thailand’s 100 percent con-
dom policy has had a profound effect on the prev-
alence of sexually transmitted diseases, including 
HIV.93 (Under this policy, the government aggres-
sively promotes the use of condoms through the 
media, distributes free condoms to sex workers, and 
sanctions commercial-sex establishments where con-
doms are not used consistently.) In Tanzania, com-
munities that managed sexually transmitted diseases 
aggressively reduced their incidence of HIV in-
fection by 42 percent.94 In addition, periodic mass 
therapy for sexually transmitted diseases, currently 
under evaluation in Uganda, shows promise.95 These 
strategies have succeeded in moderating the growth 
of the epidemic in selected populations.
Future interventions based on an increased under-
standing of host-related factors will complement the 
above approaches to help curtail the growth of the 
epidemic. First, the development of an HIV vaccine 
is crucial, not only to provide people with primary 
protection from infection, but also to reduce the 
concentration of HIV in genital secretions or to ren-
der the virus less contagious in newly infected hosts. 
However, the introduction of vaccines that were less 
than 100 percent effective could intensify the epi-
demic if risky sexual behavior increased as a result of 
the perception that vaccination conferred protection 
from infection.96
Second, topical microbicidal agents that can be 
safely employed and controlled by women must 
be developed to reduce both the susceptibility and 
the infectiousness of hosts. At least three trials of 
nonoxynol 9 formulations to prevent the acquisition 
of HIV are in progress.72 In addition, the effects of
routine vaginal douching need to be more thor-
oughly investigated.
Third, messages on safer sexual behavior could
be refocused. Recent studies show that the number
of sex partners is not as important as their concur-
rency to the propagation of the epidemic.84 Hence,
if people in newly formed partnerships delay the on-
set of sexual intercourse or use condoms consistently
for the first three months, unprotected sex in over-
lapping partnerships will be reduced in the period of
high infectiousness during primary infection.
These interventions may have the greatest impact
on the epidemic if they are directed at people in the
early stages of HIV infection. Early detection of
infections will require new approaches. Clients and
clinicians alike will need to recognize the symptoms
and signs of primary HIV disease — a mononu-
cleosis-like illness with fever, pharyngitis, adenopa-
thy, rash, and aseptic meningitis.46,97 Available viral-
amplification techniques that can detect primary
infection before seroconversion should be evaluated
for their preventive potential. In addition, kits to test
for HIV at home will provide people the option of
learning their serologic status earlier in infection and
will also reach people who might not otherwise seek
testing.
Once early infection is identified, coordination
with health departments is essential to interrupt on-
going transmission within sexual networks. Break-
ing the chain of transmission during the period of
primary and early infection is potentially the most
effective intervention. Furthermore, the early de-
tection of infection affords an opportunity for an-
tiretroviral therapy to reduce the viral burden, which
may both improve the prognosis32 and reduce infec-
tiousness.
Finally, as with other sexually transmitted diseases,
preventing the sexual transmission of HIV will re-
quire more than a single approach. A combination
of preventive strategies will be needed that is based
on an understanding of the complex interrelations
driving the epidemic of sexual transmission. Now is
the time to develop, integrate, and implement public
health policies that build on the past 15 years of
work on these interrelations. With a combined ap-
proach, using our knowledge of the epidemiology of
the spread of HIV, the biology of the virus, and the
sociology of the affected sectors of society, we can
work toward substantially reducing the sexual trans-
mission of HIV.
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